Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Teresa López‐Fernández, Daniel J. Lenihan et al.|European Journal of Heart Failure|2020Cited by 767
Genetic Variants Associated With Cancer Therapy–Induced CardiomyopathyPablo García‐Pavía, Bonnie Ky, Jon A. L. Willcox et al.|Circulation|2019Cited by 346
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerNicolò Matteo Luca Battisti, Alistair Ring, María Sol Andrés et al.|Breast Cancer Research and Treatment|2021Cited by 74
Strategies to enhance recruitment of female participants to cardiovascular research: a joint British Cardiovascular Societies’ consensus document in collaboration with the British Heart Foundation Clinical Research CollaborativeVijay Kunadian, G. André Ng, Graziella Pompei et al.|Heart|2025Cited by 7
Platypnoea–orthodeoxia syndrome: beware of investigations undertaken supineFelicity Liew, Michael I. Polkey, Fatma Gargoum et al.|Thorax|2019Cited by 3